U.S. Patent 4,900,755 (1990)7 and (2) Conte, U.S. Patent
5,738,874 (1998, filed 24 March 1995). 8
Dempski
12. Dempski describes an invention which (col. 1,
lines 12-17):
is concerned with a controlled release formulation for the
simultaneous delivery of levodopa and carbidopa in the
treatment of parkinsonism whereby the adverse reactions and
inadequacies often experienced with the administration of
standard carbidopa/levodopa combinations are minimized.
13. One carbidopa/levodopa formulation which Dempski
says is "easier to use" (Formulation No. 3) is described in
Example 4 (col. 4, lines 48-62; col. 6, line 47 and 53-54).
14. Example 4 describes a formulation containing
carbidopa and levodopa (col. 4, lines 52-53) as well as other
ingredients needed to cause the formulation to be a controlled
release formulation.
15. According to Dempski, appropriate dosages are
(col. 3, lines 51-52):
Levodopa 20-1200 mg Carbidopa 5-300 mg
Preferred dosages are (id.; see also Dempski claim 1):
Levodopa 100-400 mg Carbidopa 25-100 mg.
7 Dempski is prior art under 35 U.S.C. § 102(b).
8 Conte is prior art under 35 U.S.C. § 102(e). Applicant has not
attempted to antedate Conte (37 CFR § 1.131). In this respect, we note that
Conte is said to be based on a PCT application which is said to have been
published on 31 March 1994. The published PCT application would be prior art
under 35 U.S.C. § 102(b).
- 6 -
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007